IRC25 Antibody

What is IRC25 Antibody and what organism does it target?

IRC25 Antibody is a polyclonal antibody raised in rabbits that specifically targets the IRC25 protein from Saccharomyces cerevisiae (Baker's yeast), particularly strain ATCC 204508/S288c. The antibody recognizes epitopes on the recombinant IRC25 protein, which functions in yeast cellular processes. As a research tool, it's specifically designed for laboratory investigations and not for diagnostic or therapeutic applications . When designing experiments with this antibody, it's essential to verify that your yeast strain aligns with the reactive strains mentioned in the datasheet to ensure proper antigen recognition.

What are the validated applications for IRC25 Antibody?

The IRC25 Antibody has been validated for specific laboratory applications including Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blotting (WB). These techniques allow researchers to detect and quantify the IRC25 protein in experimental samples . When implementing these methods, it's crucial to follow the manufacturer's recommended dilutions and conditions to achieve optimal results. For Western Blotting, particular attention should be paid to sample preparation, including proper cell lysis and protein denaturation, to ensure successful antigen identification.

How can cross-reactivity be assessed when using IRC25 Antibody in complex yeast proteomic studies?

When using IRC25 Antibody in complex yeast proteomic studies, cross-reactivity assessment is crucial for ensuring experimental validity. Begin by performing control experiments with wild-type yeast strains versus IRC25 knockout strains to establish specificity baselines. Pre-absorption tests using recombinant IRC25 protein can help identify potential cross-reactions. Additionally, employ orthogonal detection methods such as mass spectrometry to confirm antibody targets in your samples.

Modern computational approaches, as described in recent antibody research, can help identify potential binding modes and cross-reactivity patterns . For complex samples, consider implementing biophysics-informed modeling to predict potential cross-reactive epitopes. Remember that even highly specific antibodies may exhibit some level of cross-reactivity, so proper experimental controls are essential for accurate data interpretation and troubleshooting unexpected binding patterns.

What are the optimal experimental conditions for using IRC25 Antibody in co-immunoprecipitation studies with yeast extracts?

For co-immunoprecipitation (co-IP) studies using IRC25 Antibody with yeast extracts, several optimization steps are critical. Begin with freshly prepared yeast extracts using gentle lysis buffers (typically containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, with protease inhibitors) to preserve protein-protein interactions. For antibody binding, use a ratio of 2-5 μg of IRC25 Antibody per 500 μg of total protein extract.

Optimize incubation conditions by testing both overnight incubation at 4°C and shorter incubations (2-4 hours) with gentle rotation. For capture, Protein A or G magnetic beads generally provide better results than agarose beads due to reduced background. Implement stringent washing steps (at least 4-5 washes) with buffers of increasing stringency to remove non-specific interactions while preserving true binding partners. Validate your results using reciprocal co-IP and consider crosslinking the antibody to beads using dimethyl pimelimidate (DMP) if heavy chain interference is a concern during downstream analysis.

How can epitope-specific binding of IRC25 Antibody be evaluated and improved for challenging experimental systems?

Evaluating and improving epitope-specific binding of IRC25 Antibody requires a multifaceted approach. Begin with epitope mapping using peptide arrays or hydrogen-deuterium exchange mass spectrometry (HDX-MS) to precisely identify binding epitopes. This information can then guide optimization strategies.

For challenging experimental systems, consider implementing the biophysics-informed modeling approach described in recent literature, which enables the identification of distinct binding modes associated with specific epitopes . This method has successfully disentangled binding modes even for chemically similar ligands. For improved specificity, custom affinity purification against the specific epitope of interest can be performed to enrich antibodies with the desired binding characteristics.

In cases where specificity remains problematic, competitive binding assays using excess IRC25 recombinant protein can help block non-specific interactions. Additionally, exploring alternative detection antibodies or implementing a sandwich assay approach may improve specificity in particularly challenging experimental contexts.

What protocol modifications are necessary when using IRC25 Antibody for immunofluorescence in yeast cells?

When adapting IRC25 Antibody for immunofluorescence in yeast cells, several critical protocol modifications are necessary. Begin with proper cell wall digestion using zymolyase (100T at 0.5-1 mg/ml) for 30-60 minutes at 30°C to improve antibody penetration while preserving cellular morphology. Fix cells with 4% paraformaldehyde for 30 minutes followed by a gentler 0.5% Triton X-100 permeabilization step (compared to mammalian protocols).

Implement extensive blocking (1-2 hours at room temperature) with 5% BSA and 5% normal goat serum in PBS to minimize the high background often encountered in yeast immunofluorescence. For primary antibody incubation, use IRC25 Antibody at a 1:100 to 1:500 dilution range and extend incubation to overnight at 4°C. Include a negative control using pre-immune serum at the same concentration to identify potential non-specific binding.

For signal amplification without increasing background, consider using a biotinylated secondary antibody followed by fluorophore-conjugated streptavidin. Counterstain with DAPI (1 μg/ml) to visualize nuclei, and mount using an anti-fade reagent with pH stabilizers to preserve fluorescence during imaging.

How should researchers troubleshoot weak or absent signals when using IRC25 Antibody in Western blotting?

When troubleshooting weak or absent signals with IRC25 Antibody in Western blotting, implement a systematic approach focusing on key variables. First, verify protein expression and loading using a positive control antibody targeting a constitutively expressed yeast protein. Optimize protein extraction by testing different lysis buffers, including those containing stronger detergents like 1% SDS for challenging samples.

For transfer optimization, consider using a lower methanol concentration (10% instead of 20%) in the transfer buffer and extend transfer time for larger proteins. If signal remains weak, implement signal enhancement strategies such as using high-sensitivity chemiluminescent substrates or exploring alternative membrane types (PVDF may offer better protein retention than nitrocellulose for certain applications).

Antibody incubation can be optimized by testing various concentrations (typically starting at 1:500 and adjusting as needed), extending incubation times (overnight at 4°C), and adding 0.1% Tween-20 to reduce background while enhancing specific binding. For particularly difficult targets, consider adding 5% polyethylene glycol (PEG-8000) to the antibody dilution buffer, which can enhance antibody-antigen interactions.

If these approaches don't resolve the issue, verify antibody activity using a dot blot with recombinant IRC25 protein and consider testing a fresh antibody lot, as antibody functionality can diminish over time or with improper storage.

What are the optimal conditions for using IRC25 Antibody in chromatin immunoprecipitation (ChIP) experiments?

Optimizing IRC25 Antibody for chromatin immunoprecipitation requires careful attention to yeast-specific ChIP conditions. Begin with 50 ml of yeast culture at OD600 0.5-0.8 and perform crosslinking with 1% formaldehyde for exactly 15 minutes at room temperature, followed by quenching with 125 mM glycine for 5 minutes. Harvest cells and prepare spheroplasts using zymolyase treatment to facilitate chromatin extraction.

For sonication, optimize conditions to generate chromatin fragments of 200-500 bp (typically 10-15 cycles of 30 seconds on/30 seconds off using a Bioruptor or similar device). Pre-clear chromatin by incubating with Protein A/G beads for 1 hour at 4°C before immunoprecipitation. For the IP reaction, use 5 μg of IRC25 Antibody per 100 μg of chromatin and incubate overnight at 4°C with rotation.

Implement stringent washing steps, including low-salt, high-salt, LiCl, and TE buffer washes to minimize background. After elution and reversal of crosslinks, purify DNA using phenol-chloroform extraction followed by ethanol precipitation rather than commercial kits for higher yield of ChIP DNA. Validate results using qPCR with primers targeting regions known to associate with IRC25 protein and include appropriate negative control regions.

What are the known limitations of polyclonal IRC25 Antibody compared to monoclonal alternatives?

Polyclonal IRC25 Antibody, while versatile, has inherent limitations compared to potential monoclonal alternatives. The polyclonal nature means batch-to-batch variation can occur, potentially requiring revalidation of optimal working conditions with each new lot. Unlike monoclonal antibodies that recognize a single epitope, polyclonal IRC25 Antibody recognizes multiple epitopes, which can be advantageous for detection but may increase background and complicate quantitative analyses.

When designing critical experiments, researchers should account for these limitations by implementing appropriate controls, including pre-immune serum controls and antigen pre-absorption tests. For studies requiring absolute epitope specificity or quantitative precision, developing custom monoclonal antibodies might be necessary despite the significant investment required.

How does the specificity profile of IRC25 Antibody compare with other yeast protein antibodies in multiplex detection systems?

In multiplex detection systems, the specificity profile of IRC25 Antibody must be carefully evaluated against other yeast protein antibodies to ensure accurate data interpretation. Polyclonal antibodies like IRC25 Antibody typically exhibit broader epitope recognition compared to monoclonals, which can be both advantageous and challenging in multiplexed systems.

When implementing multiplex immunoassays, cross-reactivity matrices should be established by testing each antibody against all target proteins individually before combining them. Recent advances in biophysics-informed modeling can be particularly valuable for predicting potential cross-reactivity in multiplex systems . These models can help identify distinct binding modes for each antibody-antigen pair and predict potential interference when used in combination.

For optimal results in multiplex systems, consider using IRC25 Antibody in combination with antibodies raised in different host species (e.g., mouse, goat) to allow for species-specific secondary antibody detection without cross-reactivity. Additionally, sequential detection rather than simultaneous detection may help minimize potential interference when working with closely related yeast proteins.

What emerging technologies might enhance the application of IRC25 Antibody in yeast research?

Emerging technologies offer exciting possibilities for enhancing IRC25 Antibody applications in yeast research. Single-cell proteomics techniques are increasingly being adapted for yeast studies, allowing researchers to examine IRC25 protein expression and localization with unprecedented cellular resolution. These approaches, combined with IRC25 Antibody detection, could reveal previously unknown heterogeneity in IRC25 function across yeast populations.

Advanced computational approaches for antibody specificity prediction, as described in recent literature, can help optimize IRC25 Antibody applications . These biophysics-informed models enable the identification of different binding modes and can predict antibody behavior across various experimental conditions, potentially allowing researchers to customize IRC25 Antibody use for specific applications.

Additionally, proximity labeling techniques such as BioID or APEX2 coupled with IRC25 Antibody could provide dynamic insights into IRC25 protein interactions in living yeast cells. This would move beyond static interaction studies to reveal temporal aspects of IRC25 function. As these technologies continue to evolve, they promise to expand the research applications of IRC25 Antibody beyond current capabilities.

How should researchers interpret contradictory results between IRC25 Antibody detection and genetic expression data?

When faced with contradictory results between IRC25 Antibody detection and genetic expression data, a systematic troubleshooting approach is essential. Begin by verifying antibody specificity using IRC25 knockout strains as negative controls to confirm that observed signals are specific to the target protein. Post-translational modifications or protein degradation can significantly impact antibody detection without affecting mRNA levels, potentially explaining such discrepancies.

Different detection thresholds between antibody-based methods and genetic techniques may also contribute to apparent contradictions. RNA sequencing typically offers greater sensitivity than antibody detection, potentially detecting expression below the antibody's limit of detection. Consider using more sensitive detection methods such as digital ELISA or single-molecule pulldown assays with IRC25 Antibody to bridge this sensitivity gap.